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Abstract 
Case report on a case of cryptic 
t(19;19)(p13.3;q13.2), involving the TCF3/E2A 
gene, detected and described by molecular 
cytogenetics in a patient with childhood B-cell 
progenitor acute lymphoblastic leukemia. 
Clinics 
Age and sex 
6 years old male patient. 
Previous history 
No preleukemia, no previous malignancy, no inborn 
condition of note  
30-day history of fever without an obvious source 
of infection. 
Organomegaly 
Hepatomegaly, no splenomegaly, enlarged lymph 
nodes (in cervical and axillary regions. Ecchymoses 
and petechiae in lower extremities.), no central 
nervous system involvement.  
 
Blood 
WBC: 1.6 X 109/l 
HB: 3.9g/dl 
Platelets: 26 X 109/l 
Blasts: 0% 
Bone marrow: Hypercellular with 45% 
lymphoblasts 
Cyto-Pathology 
Classification 
Cytology 
Presence of 45% immature blast cells with a 
moderate nucleus-to-cytoplasm ratio, evident loose 
chromatin and nucleoli (1-2 per cell) without 
granules compatible with FAB classification ALL 
L2. 
Immunophenotype 
Blast cells positive for CD19, CD79a, CD22, and 
TDT; negative for CD45, CD34, CD20, CD10, 
cyIgM, CD123, NG2, MPO, CD33, CD64, CD15, 
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CD13, CD65, CD7 and cyCD3. Compatible with B-
cell progenitor acute lymphoblastic leukemia (BCP-
ALL). 
Rearranged Ig Tcr 
Not done. 
Pathology 
Not applicable. 
Electron microscopy 
Not done. 
Diagnosis 
Progenitor B-cell lymphoblastic leukemia. 
Survival 
Date of diagnosis: 09-2012 
Treatment: Grupo Brasileiro de Tratamento da 
Leucemia na Infancia (GBTLI -99) protocol, low-
risk arm 
Complete remission: complete remission was 
obtained at D28 of treatment. 
Treatment related death: no  
Relapse: no  
Status: Alive 
Last follow up: 08-2013 
Survival: 11 months 
 
 
 
Karyotype 
Sample: Bone marrow 
Culture time: 24h 
Banding: GTG banding technique 
Results 
46,XY[20] (Figures 1 and 2) 
Karyotype at Relapse 
No relapse at that time 
Other molecular cytogenetics technics 
Fluorescence in situ Hybridization (FISH) using the 
following locus specific probes: 
ETV6/RUNX1(Abbott®), BCR/ABL (Abbott®), 
MLL break apart (Abbott®), E2A break apart 
(Cytocell®). 
Other molecular cytogenetics results 
FISH analysis showed that E2A 3' probe (covering 
164 kb 3' of the gene), labeled in green, was 
rearranged on the "q" arm of the other chromosome 
19 (Figure 3A). FISH analysis was negative for 
ETV6/RUNX1 and BCR/ABL fusion genes and 
MLL rearrangement. FISH using multicolor 
banding (MCB) applying the probe set for 
chromosome 19 (Liehr et al., 2002) also confirmed 
and refined the reciprocal translocation of 
chromosomes 19 (Figure 3B). 
46,XY.isht(19;19)(p13.3;q13.2)(5'TCF3+;3'TCF3+)
. 
 
 
Figure 1: G-banded metaphase with black arrow indicating chromosomes 19. 
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Figure 2: G-banded karyotype. 
 
 
Other Molecular Studies 
Technics: 
Semi-quantitative reverse transcription polimerase 
chain reaction (RT-PCR):  
RT-PCR were performed with one microgram of 
mRNA, treated with DNAse Amplification Grade I 
(Invitrogen) and reverse transcribed with 
Superscript II Reverse transcriptase® (Invitrogen).  
Each reaction was carried out with Taq DNA 
Polymerase (Invitrogen).  
The reactions were performed using the following 
program: 95°C 2 min and 45 cycles at 94°C for 30 
sec and 62°C for 1 min and 72°C for 1min. PCR 
product was analyzed by electrophoresis on 1.5% 
agarose gel. β-actin was used as control.  
The following primers were used:  
E2A/PBX1 - Fw, 5'- CACCAGCCTCA 
TGCACAAC - 3'/ Rev, 5'-
TCGCAGGAGATTCATCACG- 3'; β-ACTIN -Fw, 
5'- CAGCAGATGTGGATCAGCAAG -3' / Rev, 
5'- GCATTTGCGGTGGACGAT -3'. 
Results: 
The RT-PCR assay performed, disclosed the 
presence of E2A-PBX1 gene fusion (Figure 5). 
Comments 
A t(19;19) has been described as a cryptic 
abnormality involving E2A(TCF3) gene (Boomer 
et al., 2001; Brambillasca et al., 1999). Using gene 
specific probes, FISH is an efficient tool to screen 
cryptic cytogenetic abnormalities (Boomer et al., 
2001; Moorman, 2012). The case presented here 
had an unremarkable GTG banding study. The 
chromosomal abnormality was found via FISH 
screening using the E2A/TCF3 breakapart probe. 
Because of the rarity and possible prognostic 
implication of this translocation, we submitted 
material for MCB analysis (Liehr et al., 2002) and 
RT-PCR exclude the presence of the cryptic 
E2A/PBX1 fusion. The results showed that the 
breakpoint on the 19q13.2 region. This breacpoint 
observed in the present work differs from that 
previously described (19q13.4) by Brambillasca, 
1999, that descrbed the fusion TCF3/TFPT. Our 
work provides clinical and cytogenetic data for a 
child with BCP ALL carrying a novel 
t(19;19)(p13.3;q13.2). To our knowledge, this is the 
first report of a case harboring this abnormality. We 
suggest a putative gene in the breakpoint region 
might be involved in leukemogenesis. 
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Figure 3: A) E2A dual color break apart probe showing E2A 3' portion rearranged at the q arm of the other chromosome 19. B) 
MCB for chromosome 19. 
 
 
 
Figure 4: Partial karyotype showing G-banded, FISH and MCB chromosomes. 
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Figure 5: Semi-quantitative RT-PCR analysis to detect E2A/PBX1 expression. E2A/PBX1 were expressed in a patient with 
t(1;19) (positive control). The E2A/PBX1 fusion was not detected in the patient with t(19;19). β-actin was used as control. 
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